Cell therapy protocol 1

"Cell therapy protocol 1" refers to a specific clinical trial intervention involving the administration of Mesenchymal Stem Cells (MSCs). This protocol typically entails two intravenous doses of MSCs, each at 100 × 10^6 (±10%) cells, administered on Day 0 and Day 2, in conjunction with conventional medical treatment. The primary indication for this protocol, as identified in clinical trials, is Acute Respiratory Distress Syndrome (ARDS), particularly in the context of COVID-19. MSCs are known for their multifaceted therapeutic properties, including immunomodulatory, anti-inflammatory, and tissue regenerative capabilities. They function by reducing inflammatory responses, regulating the immune system, and promoting tissue repair.